Health Viewpoints

Author: Lyn Dee

  • From Ward to Home: The Real Barriers to Community-Based Care

    From Ward to Home: The Real Barriers to Community-Based Care

    Providing patient care closer to home sounds like the most obvious improvement in the world. If someone doesn’t need a hospital bed, why keep them in one? Why not support them at home, where they sleep better, eat what they’re used to, and avoid hospital-acquired infections and deconditioning? Well, because home isn’t just a place, it’s a service.

    Moving a patient from ward to home is not about moving a person from one building to another. We’re talking about moving an entire chain of support: clinical monitoring, medicines management, rehabilitation, safeguarding, transport, carer support, equipment, and a clear escalation route if something changes overnight. Hospitals are expensive, but they are also the only part of the system designed to solve uncertainty at speed. Community services can be brilliant, but they are not built to absorb unlimited acute demand on command. That’s why shifting care out of hospital ward to home is hard. And it’s why the system keeps snapping back.

    Hospital unit or ward to home realities

    In a standard hospital, the system is built around rapid decisions and rapid rescue by default. Someone deteriorates, a nurse sees it, observations trigger escalation, a doctor reviews, a specialist is called, tests are done, and treatment changes within minutes or hours. Accountability is clear. The team is in one place and there is 24/7 cover by design. 

    Community care operates differently, it is built for continuity, not constant surveillance. Care is designed to manage long-term conditions, support recovery, and prevent crises, usually through planned visits, scheduled reviews, and multidisciplinary coordination across organisations. Even where community response teams exist, they are often balancing travel time, caseload complexity, and finite staffing. This pathway also relies heavily on the reality of the home environment: whether the patient can manage stairs, the heating works, there’s a carer, they can store medicines safely, they are cognitively able to follow instructions, and whether risks such as falls, domestic abuse, or self-neglect are present.

    So, when patient risks have been clinically managed the next question is not just “can they leave?” It is or should be “what support must exist for leaving to be safe?” This distinction is where many shift-left ambitions quietly struggle. The hospital discharge decision is often framed as a single moment but in truth, it is an operational handover into a complex system that isn’t always ready to receive.

    Why the system snaps back to hospital

    Hospitals are the default not because everyone loves the hospital, but because the hospital solves four problems instantly:

    1. Time: decisions can be made now, not next week.
    2. Risk: monitoring and rescue are built into the environment.
    3. Coordination: teams and diagnostics are co-located.
    4. Certainty: responsibility sits clearly with one organisation and one clinical chain of command.

    Community-based alternatives can achieve excellent outcomes, but the system snaps back when those four needs aren’t met quickly enough, especially time and risk. When uncertainty rises, hospital becomes the safest option by default. Not always the best option, but the safest option the system can guarantee today.

    So, what are the real barriers that create this snap-back effect and keeps care in the hospital?

    Community capacity is not sitting idle

    A common misconception is that community services have slack in the system, that there are spare staff who can simply pick up what hospitals stop doing. In reality, many community teams run close to full capacity. Their demand is steady and ongoing: wound care, catheter care, medication support, frailty reviews, palliative care, long-term condition management, and post-acute rehabilitation. Adding more work often means either increasing staffing (which is slow) or displacing existing work (which creates risk elsewhere).

    Unlike a ward or hospital unit, community work also includes travel time, lone working, and high variability. Two patients labelled “needs support at home” can require radically different levels of input. One might need a single check-in and a medicine review. Another might need multiple daily visits, personal care, mobility equipment, and close monitoring. So, when hospitals try to shift more patients to the community, the system often faces a simple reality that capacity may not be readily available, and it cannot be created instantly.

    The 24/7 gap changes decisions

    Hospitals don’t just provide treatment; they provide reassurance that someone is watching. That matters most at the edges: the patient who is borderline stable, the older adult with delirium risk, the patient whose breathing is just a little worse tonight than yesterday, or the patient who should be fine but has multiple conditions and doesn’t cope well when anything changes.

    In many areas, community services are not configured for continuous monitoring or rapid overnight escalation. Even when out-of-hours services exist, they can be stretched, fragmented, or not equipped with the same diagnostics and staffing mix as acute care. This gap shapes decisions. If it’s 9pm and a clinician has a choice between sending someone home with limited overnight support or admitting them for observation (just to be safe), the default becomes admission. Not because the person definitely needs inpatient care, but because the system cannot reliably provide a safe alternative at that moment. Shift-out plans often fail on this point: community pathways can look strong on paper during office hours, but the system doesn’t experience demand only during office hours.

    Risk and accountability aren’t shared cleanly

    In acute care, risk is held by the institution and visible to the team. In community care, risk is distributed across multiple organisations, primary care, community providers, social care, and sometimes the voluntary sector. When a plan fails, it is not always obvious who owned the decision or whether the decision was reasonable given the information available at the time. This matters because often, people don’t avoid risk; they avoid unmanaged risk. If a clinician keeps a patient at home and something goes wrong, the question that follows is often framed as “why wasn’t this person admitted”? That creates a strong gravitational pull toward hospital admission when there is uncertainty.

    For a hospital ward-to-home pathway to work at scale, risk has to be designed, not assumed. For example, having clear thresholds for home management versus admission, shared escalation protocols, easy access to senior clinical advice and agreed responsibility for follow-up and review. Without that, the safest professional choice often becomes the most conservative choice: keep the person where the safety net is thickest.

    Disparity in social care and real-life home conditions

    A patient can be clinically ready for discharge but still not safe at home. Home might mean stairs with no railings and a person who can’t manage them yet, no heating and worsening respiratory problems, a carer who is untrained, safeguarding concerns, cognitive impairment with poor medication adherence or high falls risk without equipment or supervision. Social care packages (home care support) can take time to arrange. Equipment may not arrive on the same day. Home adaptations don’t happen overnight. Family support cannot always be assumed. And where there is a shortage of carers, the entire home support plan becomes fragile. This is also an equity issue.

    Home is not equally safe or equally supportive for everyone. If we push ward-to-home without addressing housing, social care capacity, and the practical realities of daily living, the burden falls hardest on people already facing disadvantage, and the system may see a rebound in the form of revisits, crisis calls, and preventable deterioration.

    Behind-the-scenes handovers are not smooth

    When handover information like basics referrals, records, medication lists, and follow-up plans don’t travel smoothly between teams, patients bounce back. Even when community services exist, the pathway can fail at the seams. Community teams need timely, accurate information: diagnosis, test results, medication changes, functional status, risk factors, and the plan. If discharge information arrives late, or is incomplete, or is not shared across the right systems, community clinicians cannot safely pick up care. The result is predictable: missed follow-ups, confusion over medication, delayed assessments, or duplicated work, and then the patient returns to hospital because things went wrong at home. This is what makes discharge feel like a cliff edge, not because community teams don’t want to help, but because the system lacks reliable handover infrastructure.

    Moving patients form hospital ward to home succeeds when handover behind the scenes is boring and dependable: simple referral criteria, one point of contact for urgent queries, a shared care plan that the patient and family understand, robust medication reconciliation and a clear responsibility and trigger for the next review. When these basics aren’t in place, the system’s safest move is to keep the patient where coordination is easiest: in hospital.

    Incentives don’t move at the speed of patients

    This is the barrier we talk around, but it sits under everything. The uncomfortable truth is that shifting care out of hospital usually creates a period where you need to fund both systems at once. Leaders are often asked to reduce acute pressure while simultaneously managing deficits. That makes invest now for savings later financially hard, even when it is strategically right. Hospitals carry fixed costs: estates, on-call cover, diagnostics, specialist staffing. You don’t save money the moment a few patients are treated elsewhere. Meanwhile, investing in community pathways requires upfront funding: recruitment, training, digital infrastructure, equipment, and often new models like rapid response or step-up/step-down services.

    When funding does not protect community build-out, it gets swallowed by immediate hospital pressures, because those pressures are visible, urgent, and measurable today. The result is a partial shift: discharge pressure increases, but the community alternative is underpowered. And then the system snaps back through readmissions, emergency department reattendance, and delayed recovery.

    Switching off the ward before the home is ready

    The biggest mistake in many shift-out strategies is treating it like a simple substitution: reduce bed base, and community will absorb the difference. In reality, you often need a bridge period, a time where you deliberately run both models. That means supporting people at home and keeping enough acute capacity as a safety buffer while the new pathway stabilises. This is not waste. It’s transition.

    The bridge period covers the messy middle: recruitment delays, learning curves, pathway refinement, trust-building between teams, data-sharing fixes, and building confidence that the community response is dependable. Without that bridge, a system that reduces acute capacity too early creates risk, and risk drives behaviour. Behaviour then pulls demand back into hospital, whether through admission decisions, longer stays, or repeat attendances. Ward-to-home fails when it’s treated as a cost-cutting exercise first and a safety redesign second. It works best when it’s treated as a reliability project: making the community alternative dependable enough that clinicians and patients trust it.

    Looking ahead

    Hospitals keep winning because they are built to manage uncertainty, risk, and time pressure with 24/7 certainty. Community care can absolutely deliver better outcomes for many patients, but only when it is resourced, connected, and trusted as a reliable alternative. If home is treated as a destination rather than a service, the system will keep snapping back. If it’s treated as an engineered pathway, with capacity, shared accountability, strong handoffs, and a deliberate bridge period, then moving patients from hospital wards to home becomes a safer, smarter way to care. Until then, the rebound isn’t a mystery. It’s the system doing what it was designed to do: choosing the only safety net it can guarantee.

  • Obesity Care Is Becoming Retail: Are Health Systems Ready for the Weight-loss Pill Era?

    Obesity Care Is Becoming Retail: Are Health Systems Ready for the Weight-loss Pill Era?

    The FDA approved Novo Nordisk’s once-daily Wegovy weight-loss pill in late December 2025, a regulatory green light that matters only if it translates into real-world prescribing and pharmacy availability. I have been drafting this article since the approval announcement, in keen anticiaption of the public product release. I finally get to fill in the blanks with verified information and publish, because obesity care is retail now; real-world orders and dispensing of the pill started officially, today!

    This morning (5 January 2026), Novo Nordisk didn’t just announce something, it changed the format of the obesity conversation. The company has now launched Wegovy as a once-daily pill in the US, with starter doses priced for self-pay patients and wide pharmacy availability. That matters because for millions of people, the barrier to GLP-1 treatment hasn’t been belief, it’s been needles, logistics, and follow-through.

    The deeper significance of this launch is not just that it’s Wegovy in another form but rather, a medication moving from a weekly injection to a daily tablet changes the shape of demand. Injections come with built-in friction: needle comfort, storage, technique, a weekly ritual, and a sense that this is specialist medicine. Pills remove some of that friction and make initiation more normal. And when initiation becomes normal, health systems inherit a new operational question: what happens after the first prescription? Novo’s launch strategy reinforces that shift because now, the clinical system must become stronger at everything that comes next, selection, support, monitoring, and maintenance.

    Reuters reports wide availability through major US pharmacies, including retail brands such as CVS and Costco, alongside telehealth partners. That combination, retail distribution plus telehealth routes, pushes obesity treatment closer to consumer channels. It doesn’t automatically make care worse. But it does change the risk profile, because consumer channels tend to scale faster than structured clinical follow-up.

    The pricing reported at launch is also best understood as a signal rather than a story in itself. Reuters reports starter doses priced at $149 per month for 1.5 mg and 4 mg, with higher doses (9 mg and 25 mg) at $299 per month, with a planned increase of the 4 mg dose to $199 from 15 April 2026.   Whether those prices feel low or high depends on context, but the strategic meaning is clear: reduce barriers to starting, then move people upward through dosing.

    Right now, it is important to anchor this discussion in clinical reality. The medication is not being launched because it is marginal; it is being launched because the evidence base is strong. Reuters reports late-stage trial results showing around 16.6% average weight loss over 64 weeks at the 25 mg dose. But if effectiveness explains why a pill exists, it does not explain whether we are ready for its scale.  Daily dosing changes adherence patterns for eaxmple, a missed weekly injection and a missed daily tablet are different behaviors. Moreover, daily regimens can fit routine more naturally, but they can also drift quietly, missed days that become weeks, inconsistent use, stop-start cycles, and symptom management done informally without clinical input.

    The launch also highlights the need to separate access from care. A pill doesn’t solve every access problem, but it reshapes what scale could look like, and it forces health systems to ask a harder question: are we ready for obesity treatment to move from a specialist, injection-led era into something closer to primary-care volume? If a health system expands access without expanding care infrastructure, it may create a short-term surge in starts followed by a long-term wave of discontinuation, complications, and public backlash. The danger is not that the medication does not work; it is that the system does not support people to use it well.

    Novo is also emphasizing readiness to meet demand, an important message after supply concerns in the broader GLP-1 category. Reuters reports Novo says it is prepared to meet demand for the oral product. Supply matters because continuity matters; obesity treatment is not a short course, it is chronic management. Interruptions can destabilize progress, increase frustration, and amplify narratives that frame obesity medication as hype rather than a legitimate long-term tool.

    Although this is a US launch, the implications are global. Once the form factor changes, public expectations shift internationally. Reuters’ reporting notes that a UK decision is expected by year-end 2026.  Whether a system is publicly funded, privately insured, or mixed, the same pressure will appear: why is a pill available “somewhere else”? why is access restricted? why is support uneven? A pill that scales quickly can accelerate those questions, and systems will need coherent answers. In effect, the success of this ‘pill era’ will depend not only on pharmacology, but on whether systems can create light-touch, scalable follow-up that prevents avoidable failures.

    The second operational shift is that pills often broaden the prescriber universe. When a therapy feels more familiar, more clinicians and more platforms are likely to offer it. That can be a positive development if it brings obesity care into mainstream chronic disease management. But it becomes risky if the medication is treated as the full intervention rather than the entry point into a structured pathway.

    Obesity treatment intersects with comorbidities, medication interactions, tolerability issues, and long-term maintenance planning. A growing cohort of patients starting treatment means a growing cohort needing guidance on side effects, dose escalation, expectations, plateaus, and discontinuation. This is where governance matters.

    If obesity care is becoming retail, then health systems need clarity on ownership. When someone starts through telehealth or a retail channel, who holds longitudinal responsibility? Who ensures the right screening happens? Who checks for red flags? Who manages escalation when side effects are severe, or when rapid weight loss intersects with other conditions? Without clear ownership, the default becomes fragmentation, and fragmentation is where avoidable harm hides.

    The Wegovy pill is not simply a new product. It is a systems test of whether we can treat obesity like the chronic, multi-factor condition it is, at the volume the public has been waiting for. The most important questions now are not only about who can obtain the medication, but about what responsible scale looks like. If more people start treatment, who funds and owns follow-up? What guardrails should exist for high-volume prescribing through consumer channels? And how do we protect long-term outcomes from short-term narratives, so that this moment becomes a step forward in chronic disease care rather than another cycle of enthusiasm followed by disappointment?

    Quick facts box

    • US launch: 5 Jan 2026 
    • FDA approval reported: 22 Dec 2025 
    • Self-pay pricing at launch (reported): $149/month (1.5 mg, 4 mg); $299/month (9 mg, 25 mg); 4 mg rises to $199 from 15 Apr 2026 
    • Availability (reported): major US pharmacies + telehealth partners 
    • Efficacy headline (reported): ~16.6% weight loss at 64 weeks in trial 

    Sources:

    • Reuters – Novo Nordisk launches Wegovy weight-loss pill in the US (5 Jan 2026).
    • Reuters – Coverage of FDA approval of oral Wegovy (Dec 2025).
    • Reuters – Trial result coverage for oral semaglutide (16.6% at 64 weeks) and launch pricing details.

  • Rethinking America’s Shift to Bilateral Aid: A New Global Health Gamble?

    Rethinking America’s Shift to Bilateral Aid: A New Global Health Gamble?

    When the United States quietly rolled out its new “America First Global Health Strategy,” it marked more than a policy update. It signaled a fundamental reimagining of how the world’s largest historical health donor intends to support countries managing epidemics, chronic conditions, and fragile health systems. But the path to this new strategic direction has been anything but smooth. A year marked by abrupt foreign aid cuts and the dismantling of USAID, the decades-old agency that coordinated much of America’s global health footprint, forms the backdrop to a shift that health experts say carries real risks. Is this a new global health gamble?

    Let’s piece together what this pivot means, by unpacking what seems to be shaping it: disruption, opportunity, skepticism, and a rapidly closing window for negotiations.

    Officials vs. Practitioners

    While U.S. officials insist the change will drive efficiency and empower national governments, global health practitioners warn that the strategy introduces new uncertainties, a narrower set of priorities, and a timeline that threatens to rush countries into agreements they may not fully understand.

    The world after the cuts

    Before the new strategy even enters the conversation, many health systems are still dealing with the fallout of unexpected U.S. foreign assistance cuts earlier this year. Organizations in multiple countries were forced to scale down or close programs overnight. Workers who had been providing testing, community outreach, maternal health services, and disease surveillance suddenly found themselves without funding. Only months later, the U.S. introduced a policy that now asks countries to rapidly commit to a new funding model.

    Rachel Bonnifield of the Center for Global Development captured the contradiction when she noted that the approach could make sense for more stable, wealthier countries, but not for the poorest ones struggling to recover. She added that the rushed cut-offs earlier in the year made the transition far harder than necessary, saying they “just cut off tremendous numbers of awards and foreign assistance programs without warning.” The logic is simple: a disrupted system is not a ready system. Yet these are the same systems now being asked to sign onto five-year bilateral compacts.

    The Strategy: built on direct deals, not global partnerships

    At the heart of the new approach is a departure from multilateralism. Instead of routing funding through global health organizations or large implementing partners, the U.S. intends to negotiate one-on-one compacts with individual countries.

    Officials argue this will streamline operations and eliminate unnecessary administrative layers. They describe a world where funding flows with fewer intermediaries, countries negotiate directly with Washington, and overhead is reduced. According to one senior State Department official, countries are eager to be “brought to the table,” and see this as an opportunity to take greater control of their systems. But others doubt whether the picture is so simple.

    A senior aid worker explained that the so-called overhead often pays for what keeps systems functional: training, sanitation, medical education, and organizational management. As they put it, “A hospital is more than just a doctor and the medications.” Without these invisible systems, the visible ones collapse.

    The shift also sidelines NGOs, private health groups, and community organizations that often reach populations national ministries struggle to serve. Vulnerable groups, those in remote communities, informal settlements, or areas where government services don’t reach, may find themselves cut out.

    Deadlines: compressed timeline and high stakes negotiations

    The strategy sets an end-of-year deadline for completing agreements with the countries that receive the bulk of U.S. health funding. Negotiation teams have already visited 20 nations, and diplomats are speaking with dozens more.

    But speed is becoming a central concern. One experienced aid worker said many lower-income countries simply lack the capacity to negotiate under such pressure. If they need U.S. support to keep their programs running, and most do, they may feel compelled to sign whatever is put before them. As one put it, “They will agree to what they have to agree to, to keep going.”

    This sense of being cornered contrasts sharply with the U.S. narrative of collaborative partnership. Meanwhile, the U.S. government claims that early pilot programs in Kenya, Zambia, and Nigeria demonstrate the model’s success. But details on what success means, coverage expansion, cost reduction, improved outcomes, remain unclear.

    A narrower focus: what’s missing

    One of the most striking facts about the new strategy is what it leaves out.

    The U.S. will concentrate its efforts on:

             •       HIV/AIDS

             •       Tuberculosis

             •       Malaria

             •       Outbreak response

    Traditionally, U.S. global health engagements also supported:

             •       Immunization coverage

             •       Maternal and child health

             •       Nutrition

             •       Reproductive health

             •       Neglected tropical diseases

    But these areas receive little to no attention under the new framework. Bonnifield described these absences plainly: “There is minimal discussion of immunization, for example, or reproductive health … those are loudly absent.” The Modernizing Foreign Assistance Network (MFAN), a bipartisan advocacy group, also warned that the policy reflects an unusually narrow definition of “global health.” This narrowness matters. Health sectors do not operate in silos. Weak maternal health affects neonatal outcomes. Poor nutrition affects TB resilience. Limited immunization coverage increases outbreak vulnerability. Cutting one part of the ecosystem destabilizes all of it.

    Data: the most controversial piece

    One aspect of the new strategy that is raising confidential but widespread concern is the long-term data requirement. According to aid officials, the standard compact requests that countries share their epidemiological data with the U.S. for 25 years. While some nations have negotiated shorter terms, fears remain about:

    • how the data will be stored,
    • who will control it,
    • which private entities will access it, and
    • whether countries providing data will directly benefit from future innovations.

    A senior aid worker described it bluntly: “It’s not a data-sharing agreement. It’s a data-giving agreement.” This raises worry that pharmaceutical companies could use the data to advance research or commercial products without guaranteeing that newly developed treatments will be accessible or affordable to the countries that provided the raw information. The transactional framing marks a shift away from the Soft-Power-For-Good model that traditionally characterized U.S. global health leadership.

    Priorities: ties to U.S. business interests

    Perhaps the most symbolic indicator of the strategy’s new priorities is the announcement that the U.S. will provide “up to $150 million” to an American drone company to supply medical products in five African countries. While drones can indeed offer real logistical advantages in remote areas, the emphasis on a U.S. private firm underscores the strategy’s commercial dimension.

    One senior official described the new compacts as being modeled after “modern private-sector contracts” that encourage countries not just to improve their systems, but also to “deepen connections to the United States” and create market opportunities for American industries. This approach is consistent with the administration’s broader economic agenda, but it also shifts the character of global health assistance toward a more transactional, business-oriented model. A senior global health official acknowledged this change, saying, “It’s a lot more transactional than we’ve been before.”

    Concerns about capacity at home

    The strategy transfers enormous responsibility for global health management to the State Department, an agency that, according to MFAN’s report, “currently lacks sufficient staffing and systems” to manage what USAID previously oversaw.

    Managing complex bilateral health compacts, overseeing multi-country implementation, ensuring accountability, monitoring data agreements, and evaluating outcomes are tasks requiring specialized technical expertise, administrative architecture, and dedicated personnel. In short: it’s unclear whether the U.S. government is ready for the system it is attempting to build.

    Vision: high-risk with unknown outcomes

    It is possible that the new bilateral approach could push countries toward stronger ownership and greater long-term sustainability. Some officials genuinely believe this shift will be transformational. But health experts remain cautious, noting that the strategy asks fragile systems to take on more just months after losing steady U.S. support.

    Jeremy Konyndyk, president of Refugees International and former senior USAID disaster-aid and global health official summarized the concern with a sharp metaphor, arguing that instead of a careful transition, the U.S. has “just pushed Humpty Dumpty off the wall and left the country to pick up the pieces.”

    In conclusion…

    Whether this new chapter strengthens global health or strains it further will depend not only on political intention but also on implementation, timing, and the real capacity of both sides to manage the risks.

    For now, what the world is seeing is a major gamble: a compressed negotiation timeline, fewer intermediaries, narrower priorities, long-term data commitments, and a stronger commercial footprint. It is bold. It is disruptive. And, as many experts note, it is high-risk.

    Source articles:

    1. U.S. Department of State (2025). America First Global Health Strategy. Official policy document published on state.gov.

    2. CNN – Kent, L. & Hansler, J. (2025). “The US has released an ‘America First Global Health Strategy.’ Health experts warn it is risky.” CNN Politics, 26 Nov 2025.

    3. Center for Global Development – Bonnifield, R. (2025). “Unpacking the US’s New Global Health Strategy.” CGD Blog, Oct 2025.

    4. Think Global Health (2025). “Questions for the America First Global Health Strategy.” Council on Foreign Relations, Nov 2025.

  • The Hidden Crisis: Reflections on Stroke and the Fight for Better Care in West Africa

    The Hidden Crisis: Reflections on Stroke and the Fight for Better Care in West Africa


    Unseen Battles

    One year ago today, on the 1st November, my father passed away following complications from stroke. As I reflect on his life, I am reminded that his story is shared by thousands of families across West Africa, stories of strength, faith, and quiet endurance in the face of a devastating illness that too often claims lives far too soon. This post is both a tribute to his memory and a reminder of the urgent need to confront the growing burden of stroke in our region.


    Understanding Stroke

    A stroke occurs when blood flow to part of the brain is interrupted or reduced, depriving brain tissue of oxygen and nutrients. Within minutes, brain cells begin to die. The two main types are ischemic stroke, caused by a blockage such as a blood clot, and hemorrhagic stroke, caused by bleeding in the brain. Globally, stroke is the second leading cause of death and a major cause of long-term disability. Yet, what makes it particularly tragic is that up to 80% of strokes are preventable through the control of modifiable risk factors such as high blood pressure, diabetes, smoking, and unhealthy diets.

    In many African settings, however, the warning signs of stroke are not widely recognized, and emergency response systems are weak or underdeveloped. The classic warning signs can be remembered with the acronym FAST:
    F – Face drooping
    A – Arm weakness
    S – Speech difficulty
    T – Time to call for help immediately

    The African Reality
    Africa, particularly sub-saharan Africa, is experiencing a silent but alarming rise in stroke cases. According to the World Health Organization (WHO) and the Global Burden of Disease Study, Africa has some of the highest stroke mortality rates in the world, estimated at over 100 deaths per 100,000 people annually, compared to fewer than 50 in most high-income regions.

    In West Africa, studies from Nigeria, Ghana, and Cameroon reveal a disturbing trend: stroke is affecting people at younger ages, often in their 40s and 50s, decades earlier than in Western countries. Urbanization, sedentary lifestyles, high salt consumption, and limited access to preventive healthcare are driving this shift.

    Hypertension remains the single most important risk factor, yet millions remain undiagnosed or untreated. Many people only discover they have high blood pressure after suffering a stroke. Limited access to affordable medication and the perception that “feeling fine” means being healthy continue to hinder prevention.

    Why Stroke Outcomes Remain Poor
    When it comes to stroke, time is brain, every minute counts. But in much of Africa, emergency response is delayed by multiple barriers:

    • Low awareness of stroke symptoms means people often seek help too late.
    • Transportation challenges and the absence of reliable ambulance systems prolong the time to hospital arrival.
    • Financial constraints lead to delayed decision-making, as families must weigh treatment costs against household budgets.
    • Limited stroke units, specialized hospital departments equipped to handle acute stroke care, are rare, even in urban tertiary hospitals.

    In many facilities, brain imaging such as CT or MRI is unavailable or unaffordable, making accurate diagnosis difficult. As a result, treatment decisions often rely on symptoms rather than scans, leading to suboptimal outcomes.

    Life After Stroke: The Unseen Struggle
    For those who survive, life after stroke is often a long and uncertain journey. Recovery requires rehabilitation therapy, including physiotherapy, speech therapy, and occupational therapy, services that are either unavailable or too expensive for most families. Care often falls to relatives, who provide support with little training or external help. The burden, emotional, financial, and physical, can be overwhelming. In some communities, stroke survivors face stigma, being viewed as cursed or “spiritually attacked,” which further isolates them.

    My father’s journey reminded me how even the most resilient and disciplined individuals can find themselves vulnerable in systems not built for recovery. His determination inspired those around him, but it also exposed the gaps that so many families continue to face.

    Hope and Progress: Changing the Story
    Despite the challenges, there are reasons for hope. Across Africa, a growing movement is emerging to improve stroke prevention and care:

    • The African Stroke Organization (ASO), established in 2020, has been leading collaborative research, advocacy, and capacity building across the continent.
    • Community-based screening programs for hypertension and diabetes are expanding in Ghana, Nigeria, Kenya, and South Africa, supported by the WHO’s PEN (Package of Essential Noncommunicable Disease Interventions) program.
    • Mobile health initiatives, such as SMS reminders for medication adherence and blood pressure monitoring apps, are being piloted to improve long-term control of risk factors.
    • Public awareness campaigns, often led by medical societies and NGOs, are bringing stroke education to churches, workplaces, and radio talk shows, helping people recognize early warning signs.
    • While these steps are small compared to the scale of the challenge, they represent a shift in mindset, from reactive to preventive, from despair to determination.


    A Call to Action

    Tackling stroke in Africa requires a multi-level response:

    • Governments must integrate stroke care into national non-communicable disease policies and ensure essential medications remain affordable.
    • Health institutions must strengthen emergency systems, train more neurologists, and establish dedicated stroke units.
    • Communities and faith-based groups can play a vital role by promoting blood pressure checks and sharing accurate health information.
    • Individuals can take responsibility for regular screening, healthy eating, and exercise, because prevention begins long before crisis strikes.


    In Loving Memory
    As I write this, I think of my father’s courage and faith, even in illness. His life embodied service and discipline, and his passing deepened my understanding of how fragile, yet precious, health truly is.

    The KODAN Foundation, a nonprofit memorial established in his honor, seeks to carry that same spirit forward, to uplift others, spread hope, and champion causes that make a difference.

    If this reflection reaches even one person who decides to check their blood pressure, learn the signs of stroke, or support a loved one through recovery, then his legacy, and the purpose of this message, continues to live on.

    Sources / Helpful Resources

    • Owolabi, M. O., et al. (2023). The African Stroke Organization roadmap for stroke prevention and care in Africa. Lancet Neurology, 22(4), 308–322.
    • World Health Organization (2021). Package of Essential Noncommunicable (PEN) Disease Interventions for Primary Health Care in Low-Resource Settings, 2021 update. Geneva: WHO.
    • World Health Organization (2023). Cardiovascular diseases (CVDs): Key facts. https://www.who.int/news-room/fact-sheets/detail/cardiovascular-diseases-(cvds)
  • The Untapped Power of African Indigenous Foods: Can they help in Obesity Prevention

    The Untapped Power of African Indigenous Foods: Can they help in Obesity Prevention

    Over the past decade, the food landscape across Africa has been changing rapidly. In cities like Accra (Ghana), Lagos (Nigeria), and Nairobi (Kenya), Cape Town (South Africa), fast-food outlets, imported snacks, and processed cereals are becoming everyday staples. At the same time, rates of obesity, diabetes, and hypertension, once considered “Western problems”, are rising sharply across the continent. According to the World Health Organization, obesity in Africa has nearly tripled since 1975. Many experts attribute this to urbanization, marketing, and modern lifestyles. But there’s another part of the story that rarely gets told: the quiet disappearance of traditional African foods from everyday diets. What if the same untapped power of African indigenous foods past African generations relied on, simple, wholesome, and locally grown, hold some of the answers to this global health challenge? Let’s dive in!

    A Shift Away From Traditional Diets

    In times past, majority of Africans were raised on meals built around yam, plantain, kontomire stew, groundnut soup, and beans. These meals weren’t just tasty, they were nutrient-dense, filling, and balanced.

    But today, across many African cities, there’s been a nutrition transition:

    • Traditional foods are being replaced with fast food, instant noodles, white bread, and sugary drinks.
    • Supermarkets stock imported cereals and snacks that are marketed as “modern” or “healthy.”
    • There’s a perception among some younger people that local foods are “old-fashioned” or “poor man’s food.”

    The result? Calorie-dense but nutrient-poor diets, contributing to weight gain and lifestyle diseases. And yet, the very foods being sidelined are often lower in calories, higher in fiber, and richer in micronutrients than the imported alternatives.

    The Nutritional Power of Indigenous Foods

    Let’s take a closer look at just a few examples:

    Kontomire (Cocoyam Leaves): This leafy green is the star of Ghana’s famous kontomire stew. Nutritionally, it’s rich in beta-carotene (Vitamin A precursor), iron, calcium, and dietary fiber. It supports eye health, helps reduce anemia risk, and is low in calories.

    Why it matters for obesity: Fiber + nutrient density = more satiety, fewer empty calories. A hearty kontomire stew with yam or plantain fills you up in a way that fried rice and soda simply don’t.

    Millet and Sorghum: For centuries, these grains were staples across West and East Africa. They’re gluten-free, high in fiber, and have a lower glycemic index compared to polished white rice.

    Why it matters: Unlike refined carbs, millet and sorghum release energy slowly, reducing blood sugar spikes. This is critical for diabetes prevention and weight management. These examples aren’t “new discoveries.” They’ve been part of African diets for generations. What’s missing is the recognition and integration of these foods into modern nutrition guidance.

    Bambara Beans: Often overlooked, bambara beans are sometimes called the “complete food” because they contain a good balance of carbohydrates, protein, and fat. They’re resilient, drought-tolerant, and grow where other crops fail, making them a food security treasure.

    Health impact: High in plant protein and fiber, they improve satiety and stabilize blood sugar. Diets rich in legumes are consistently linked to lower obesity risk.

    How Traditional Meals Support Satiety and Metabolic Health

    One reason our grandparents’ plates kept people full for hours is the combo of fiber-rich greens, legumes, and slow-release starches. Leafy stews like kontomire add volume and micronutrients for very few calories. Legumes, bambara beans, cowpeas, black-eyed beans, bring plant protein and soluble fiber that blunt blood-sugar spikes and increase satiety. Whole grains and roots, millet, sorghum, unripe/ripe plantain, yam, digest more slowly than refined imports, so energy is released steadily instead of all at once. Just as important is how we cook: boiling, steaming, grilling, stewing and baking generally use less added fat than deep-frying. When you pair a fiber-dense stew, a legume, and a smart carb, you get a plate that’s satisfying, nutrient-dense, and naturally portion-controlling, without calorie counting or exotic ingredients.

    Why This Matters for Obesity Prevention

    Obesity is a complex issue, influenced by genetics, lifestyle, and environment. But diet remains at the heart of prevention and management. Indigenous African foods offer three key advantages:

    • Satiety without excess calories: High fiber and protein content means you feel full longer. A bowl of beans or millet porridge sustains energy better than a pastry or instant noodles.
    • Nutrient density: These foods deliver vitamins and minerals alongside calories. That’s the opposite of processed imports, which often deliver calories without nutrition.
    • Cultural acceptability: Unlike imported “diet foods,” indigenous foods are familiar, affordable, and tied to cultural identity. That makes people more likely to adopt them long-term.

    The Missed Opportunity

    Here’s the challenge: Despite their benefits, indigenous foods are often absent from public health campaigns, dietitian advice, or popular calorie-tracking apps. Instead, the “obesity conversation” is dominated by Western diet templates, Mediterranean diets, keto, intermittent fasting, with little cultural adaptation.

    This creates barriers:

    • Nutritionists may struggle to recommend local foods if they don’t have reliable nutrient data.
    • Policymakers may overlook these foods in dietary guidelines.
    • Families may believe that imported foods are healthier simply because they’re promoted more.

    In short: Africa’s own foods are being ignored in the fight against obesity, even though they could be part of the solution.

    The Policy Blind Spot in Obesity Prevention

    Despite clear links between diet and obesity, most public health strategies in Africa, and even international obesity-prevention frameworks, still revolve around imported dietary models. Campaigns promote Mediterranean diets or Western-style “balanced plates,” but rarely feature local grains, beans, or leafy greens. This disconnect is partly historical: early nutrition research in Africa was heavily influenced by Western institutions that studied malnutrition, not obesity. As lifestyles changed, the research agenda didn’t keep pace. So today, while obesity rates soar, policymakers lack culturally relevant nutrition data and examples.

    Imagine if national guidelines emphasized kontomire stew, millet porridge, or bambara bean dishes instead of wheat bread or processed cereals. Schools, hospitals, and community programs could teach people to eat healthfully without abandoning familiar flavors. Until indigenous foods appear in policy and prevention messaging, the fight against obesity will always feel like someone else’s imported solution, not a homegrown one.

    The Good News

    There’s a growing movement to reclaim indigenous foods as both cultural heritage and public health tools. Across Ghana, Nigeria, Kenya, and beyond, chefs, nutritionists, and researchers are rediscovering local foods and reframing them as powerful allies for health. Imagine if obesity prevention programs highlighted kontomire stew or millet porridge as much as they do salads and smoothies. Imagine if school feeding programs leaned on bambara beans and sorghum instead of imported wheat products. Not only would this improve health outcomes, but it would also support local farmers and economies.

    A New Generation Reclaiming the Plate

    Across the continent and in the diaspora, a quiet food revolution is brewing. Young chefs, nutritionists, and innovators are rediscovering and modernizing traditional ingredients. In Ghana, culinary entrepreneurs are creating fonio cereals and bambara bean snacks. In Nigeria, wellness coaches promote millet-based smoothies as high-protein breakfast options. African food bloggers in London and New York are teaching global audiences how to make kontomire or egusi stews with local substitutes. These efforts matter because they reframe indigenous foods as modern and aspirational, not outdated. They also make healthy eating relatable, proof that you can honor culture while meeting today’s nutrition needs. If this movement grows, obesity prevention will no longer feel like restriction; it will feel like cultural pride on a plate.

    Closing Thoughts

    Africa’s obesity crisis won’t be solved by quick fixes or imported diet trends. It requires a return to the foods that sustained communities for centuries, foods that are affordable, accessible, and culturally meaningful. Indigenous African foods are not just relics of the past. They’re untapped tools for building a healthier future.

    Next time you’re planning a meal, think about how you can add more of these foods back onto your plate. And I’d love to hear from you: Which indigenous food keeps you feeling full and energized?

  • Why Indigenous African Foods Deserve a Place at the Global Nutrition Table

    Why Indigenous African Foods Deserve a Place at the Global Nutrition Table

    When you hear the word superfood, what comes to mind? Quinoa. Chia seeds. Kale. Those are great, but here’s something I’ve often wondered: why don’t we ever hear about native or indigenous African foods like Kontomire, Bambara beans, or Fonio in the same conversations? Why are these lacking on the global nutrition tables and databses commonly used around the world? Let’s dive in!

    Growing up in Ghana, these foods were part of everyday meals. They weren’t exotic or trendy; they were just food. But as I’ve stepped into the wider health and nutrition space, I’ve realized how invisible our indigenous foods are in global discussions. And that invisibility matters more than we think.

    The Global Superfood Bias

    The global health and wellness industry has a way of putting certain foods on a pedestal. Marketing dollars, research funding, and Western dietary guidelines spotlight a select group of plants and grains, often not the ones from Africa.

    Meanwhile, our indigenous foods, rich in nutrients, steeped in culture, and perfectly suited for local climates, rarely get mentioned. They’re under-researched, under-promoted, and under-recognized. And yet, these foods are every bit as powerful as the ones sitting on health food store shelves.

    What’s at Stake

    • Health: Many indigenous foods are nutrient-dense and play a role in preventing chronic diseases.
    • Economy & Sustainability: If more people valued these foods, it could boost local farming, reduce reliance on imports, and strengthen food security.
    • Cultural pride: Indigenous foods carry history, identity, and tradition of a people. Recognizing them on the global stage validates that heritage.

    Hidden Gems From African Kitchens

    Let me give you a taste of what I mean:

    • Kontomire (cocoyam leaves), If you’ve ever had kontomire stew in Ghana, you know how hearty and comforting it is. Nutritionally, it’s high in fiber, antioxidants, and iron, yet most calorie-tracking apps don’t even list it.
    • Fonio, An ancient grain, naturally gluten-free, rich in iron, and good for blood sugar control. Cooked in minutes, it’s sometimes called the “lazy person’s rice,” but it’s a powerhouse in disguise.
    • Bambara beans, A protein-packed legume that grows in poor soils where other crops fail. Long considered “poor man’s food,” but in truth, it’s one of the most resilient and nourishing legumes Africa has to offer.

    These are just three. There are hundreds more, each with its own story.

    The Data Gap

    Another key point is, even though organizations like the FAO have published food composition tables for parts of Africa, and some national databases exist, the truth is that many indigenous foods are still missing or under-researched. This gap has ripple effects: nutritionists can’t confidently recommend local diets without reliable numbers; policymakers struggle to build food-based guidelines that reflect what people actually eat; and families themselves may undervalue traditional foods because they don’t have access to clear, trusted information.

    Lastly, food is not just about nutrients; it’s about culture, identity, and equity. And leaving African foods out of the global table is leaving part of the story untold.

    Time to Set a Bigger Table

    In conclusion, indigenous African foods have been missing from the conversation about global nutrition for far too long. There has been pockets of work done by local researchers in some African countries but these are very limited, eg FAO database of South Africa. That needs to change. Not because they should replace quinoa or kale, but because they deserve a place alongside them.

    Join the Conversation

    Leave a comment below, and let’s start giving our foods the recognition they deserve, from a health and nutrition value perspective.

  • Weight-Loss Drugs: Whose decision is it to use them?

    Weight-Loss Drugs: Whose decision is it to use them?

    A Big Question Behind the Buzz

    Ozempic. Mounjaro. Wegovy. Zepbound. These names have exploded into everyday conversations on social media, at the doctor’s office, and even around the dinner table. For some, these injections are life changing. But here’s the messy question: who really gets to decide if someone can use them? Let’s dive in !

    Key Takeaway: The rise of weight-loss injections has created excitement, but access often depends on forces outside of the patient’s control.

    The Science in Simple Terms

    These medications are known as GLP-1 receptor agonists. They mimic a natural hormone that regulates appetite and blood sugar. The result? You feel full faster, eat less, and keep blood sugar steady. That often means losing 10-20% of body weight, unprecedented for older drugs. But they only work while you’re taking them. Stop, and the weight usually returns. It’s not a quick fix; it’s a long-term therapy.

    Key Takeaway: GLP-1 drugs are effective, but they’re a commitment, not a one-time cure.

    The Ideal World: Shared Decision-Making

    In healthcare, the gold standard is shared decision-making. You and your doctor weigh the risks, benefits, and your personal goals. With GLP-1s, that means discussing side effects, costs, and whether you’re ready for a long-term plan.

    Key Takeaway: In theory, the decision belongs to the patient and doctor working together.

    The Reality Check: Insurers Hold the Power

    Here’s the twist: even if you and your doctor agree, your insurer may still say no. At around $1,000–$1,300 a month, the cost is out of reach for most people. Many insurers only cover the drugs for diabetes, not obesity. Some impose strict limits, like only covering two years of treatment.

    Key Takeaway: Insurance companies and costs often dictate access, overruling patient and doctor choices.

    Real Stories: Between Hope and Frustration

    One young woman lost 50 pounds on tirzepatide, felt healthier than ever, and had her doctor’s support. But her insurance cut her off because she didn’t meet BMI requirements. She was forced to switch to another drug that didn’t work as well. Meanwhile, others describe these drugs as life-changing, claiming improved health, mobility, and confidence. But whether you access them can come down to luck or financial privilege.

    Key Takeaway: Patient experiences highlight both the promise of these drugs and the unfair barriers that block access.

    Beyond the Official Channels: The Black Market

    Some patients, unable to afford the official products, turn to unregulated online sellers or compounding pharmacies. These alternatives are cheaper but risky, dosing errors and impurities have already led to overdoses.

    Key Takeaway: When the system says no, people still find a way but not always safely.

    A Global Lens: WHO’s Stance

    The WHO recently on 5 September 2025, added GLP-1 drugs to its Essential Medicines List, signaling that they’re important for public health. But recognition doesn’t equal access. Insurers and policymakers still act as powerful gatekeepers.

    Key Takeaway: Even global recognition can’t guarantee personal access—local systems still control the outcome.

    Final Thoughts: Who Really Decides?

    On paper, it should be you and your doctor. In practice, insurers and costs often make the final call. Until affordability and coverage improve, patients remain stuck between hope and bureaucracy.

    Key Takeaway: The decision to use weight-loss drugs isn’t always truly yours, and that’s the uncomfortable truth.

  • WHO Adds Weight-Loss Drugs to the Essential Medicines List: What It Means for the Rest of Us

    WHO Adds Weight-Loss Drugs to the Essential Medicines List: What It Means for the Rest of Us

    A Landmark Announcement

    The World Health Organization (WHO) just shook things up: On 5 September 2025, WHO added GLP-1 drugs for obesity and diabetes to its Essential Medicines List (EML), and urged pharmaceutical companies to develop affordable generic versions. Drugs like Ozempic and Mounjaro have officially been added to the Essential Medicines List; a guide usually reserved for lifesaving treatments like antibiotics or HIV medication that countries are urged to prioritize. So what happens when weight-loss injections join that club? Let’s dive in!

    Why This Matters Globally

    In essence, WHO is declaring that obesity and diabetes deserve the same level of attention as other major health conditions. This is a huge milestone. By putting GLP-1 drugs on the list, WHO is saying: obesity and diabetes deserve the same level of attention as other major health conditions. When the world’s top health body calls a drug “essential,” it signals to governments, insurers, and aid organizations that these medications are not luxury treatments but vital tools in tackling global health challenges.

    For years, obesity was brushed off as a lifestyle problem. WHO’s move flips that narrative. By putting GLP-1s on the Essential Medicines List, the organization is saying obesity and diabetes are serious medical conditions that deserves medical solutions and treating these with modern drugs is not optional, it is essential. This decision reframes obesity as a medical condition worthy of serious treatment.

    The Good News: What Could Change

    WHO’s move could eventually make GLP-1 drugs more visible, affordable, and globally accessible. Key changes that this can bring include:

    • Visibility: Obesity treatment gets global recognition, reducing stigma
    • Hope for Generics: WHO is urging affordable versions, which could bring prices down
    • Global Reach: Countries with rising diabetes rates could gain access if cheaper supplies become available

    The Challenges: Symbolism vs. Reality

    But let’s be clear, putting a drug on a list doesn’t automatically make it appear on pharmacy shelves. Many “essential” medicines still face shortages. GLP-1 drugs remain among the most expensive treatments today, with demand already outpacing supply. That opens the door to more black-market sales and counterfeit products. Unless affordability and regulation improve, access will remain uneven. What is important to note here is that symbolism doesn’t guarantee availability, cost and supply are still major barriers.

    What It Means for Ordinary People

    If you’re living with obesity or diabetes, this decision won’t change your access overnight. Insurance, national health systems, and personal finances still matter more in the short term. But it does set the stage for future progress. It validates patient struggles and says: your condition is real, serious, and deserves medical solutions. Right now, we are seeing only little changes day-to-day, but the WHO decision lays the foundation for future access.

    The Ripple Effect: Looking Ahead

    Historically, when WHO adds a drug to its list, it pressures governments to negotiate better prices, encourages pharma to increase production, and eventually paves the way for generics. Imagine a world where someone in Ghana or India can access these same drugs through public health systems, not because they’re wealthy but because they’re considered essential. That’s the long-term promise of this decision. The real impact may be seen years from now, as the decision pushes prices down and broadens access globally.

    Final Thoughts: A Symbolic Win, With Work to Do

    This move by WHO is a milestone but not the finish line. It won’t magically make GLP-1 drugs affordable tomorrow, but it changes the conversation. It signals to patients: you matter, your condition matters, and your treatment matters. WHO has opened the door. Now governments, insurers, and pharma must decide how wide it will swing.

  • AI Skin Cancer Detection: Is It Fair for Everyone?

    AI Skin Cancer Detection: Is It Fair for Everyone?

    Imagine a Mole Checker in Your Pocket

    Think about snapping a photo of a mole with your phone and finding out right away if it might be skin cancer. That’s the promise of new artificial‑intelligence tools. They can analyze thousands of images faster than any doctor and spot patterns humans might miss. In a Stanford Medicine study, healthcare workers who used AI alongside their own judgment diagnosed skin cancer more accurately than those working without it. Even experienced dermatologists improved a bit, while nurses and family doctors saw the biggest jump. Early detection saves lives, so a tool that helps catch cancer sooner seems like a win for everyone. Truly everyone? Let’s dive in!

    But here’s the catch: will these apps and algorithms work just as well for people with darker skin? Many of the images these systems learned from show light‑skinned patients. That imbalance raises big questions about fairness and effectiveness. Let’s explore what’s going on.

    Data Gaps: When AI Doesn’t See Dark Skin

    AI learns by example. If it sees lots of examples of one type of skin, it gets better at recognizing that type. Unfortunately, most publicly available skin‑lesion databases are loaded with images of light skin. A 2021 analysis of 21 databases found that only 2,436 out of 106,950 images had skin‑tone information. Of those, ten images were from people recorded as having brown skin and just one image showed a person with dark brown or black skin. Researchers also noted that none of the images with ethnicity data came from individuals of African, African‑Caribbean or South Asian backgrounds.

    It’s not just the training databases. Medical textbooks and lecture slides aren’t much better. A Stanford study used a machine‑learning tool to scan thousands of images in dermatology training materials and found that only about one in ten images showed brown or black skin. If future doctors rarely see how diseases look on darker skin, the AI they help train won’t see it either.

    Hidden Bias in the Building Process

    Lack of diverse data isn’t the only problem. Bias can creep in at every stage of developing an AI model. First, the images themselves: when researchers choose photos to train a model, they might select “clear” or “textbook” examples that tend to come from light‑skinned patients in clinic settings. Second, the people labeling these images may be less familiar with how conditions appear on darker skin. Third, the final model may never be tested on a diverse group before it’s published.

    These hidden biases show up in performance. In a recent review of AI tools for dermatology, researchers looked at program developed over a decade and found that they almost always performed worse on skin of color. In fact, only about 30 % of the program they examined included any data specifically from people with darker skin tones. When a system rarely sees examples of melanoma on brown or black skin, it’s no surprise it misses most of those cases. That’s not just an academic problem; it’s a potentially life‑threatening one.

    Photo Quality Matters Too

    Another piece of the puzzle is the way images are captured. A mole photographed under bright clinic lights with a special camera looks very different from a photo taken at home on a phone. Lighting, focus and exposure can blur important details, especially on darker skin. In the past, cameras were literally calibrated for lighter complexions, and while modern devices are more inclusive, automatic settings can still struggle with very light or very dark subjects. If the AI was trained mostly on clear, high‑quality clinic images, it may not work well on grainy phone photos, which often come from patients of color.

    Researchers have also observed selection bias: “good” images i.e. sharp, close‑up pictures showing textbook examples of a lesion, are more likely to be chosen for model training, while “messier” photos, which might include many from darker‑skinned patients, are left out. This means the model isn’t exposed to the variety of real‑world images it will encounter.

    What Happens If We Do Nothing?

    Ignoring these gaps has real consequences. Skin cancer is common and catching it early makes a big difference. Regular skin checks can spot potential problems before they become dangerous, and early treatment is more successful. For serious melanoma, early detection can mean a 98 % five‑year survival rate. People of color already tend to be diagnosed later and have worse outcomes than people with light skin. If AI tools reinforce those disparities by missing cancers on dark skin or giving false reassurance, they could delay diagnosis even further.

    There’s a trust issue too. If communities see that these tools don’t work well for them, they may mistrust not only AI but healthcare more broadly. On the flip side, if doctors rely too heavily on AI and don’t recognize its blind spots, they might overlook concerning lesions on brown or black patients. Instead of closing the gap in care, we risk widening it.

    Looking Forward – A Path Toward Fair and Effective AI

    The good news is that these problems are fixable. Here are a few ways forward:

    • Diversify the data: The most straightforward solution is to gather more images of skin conditions on darker skin tones. Initiatives like Stanford’s Skin Tone Analysis project and Google’s Skin Condition Image Network are working to create datasets that better reflect the full spectrum of skin colors.
    • Be transparent: Developers should clearly report what kinds of images are used to train and test their models. This makes it easier to spot gaps and biases before a tool is widely released.
    • Include diverse teams: Having people from different backgrounds involved in building and testing AI can help catch blind spots. If your team includes dermatologists and patients of color, you’re more likely to notice when the model fails on those populations.
    • Improve image collection: Encourage patients to submit photos with good lighting and provide simple instructions on how to capture clear images at home. Training AI on a wide range of photo quality, from professional to smartphone photos, will make it more robust.
    • Educate clinicians and patients: Doctors need to be aware of how skin cancer looks on all skin tones, and patients should know that melanoma can affect anyone. Debunking myths like “skin cancer only happens to fair‑skinned people” helps everyone take skin health seriously.

    Final Thoughts

    AI has incredible potential to make skin cancer screening faster and more accessible, especially in places where dermatologists are scarce. Early studies show that doctors, nurse practitioners and medical students all improve their diagnostic accuracy when AI assists. That’s worth celebrating. But these tools are only as good as the data and design behind them. If we let them mirror old biases, we risk leaving some patients behind.

    Fairness isn’t a nice‑to‑have; it’s essential. Building AI that works for everyone means taking a hard look at whose skin the algorithms “see,” how images are gathered and labeled, and who gets a seat at the table during development. With thoughtful action now, we can ensure that the mole checker in your pocket works equally well for all skin tones and that AI’s promise truly benefits everyone.

    References

    Nicola Davis, “AI skin cancer diagnoses risk being less accurate for dark skin – study,” The Guardian (November 9, 2021).

    Andrew Myers, “AI Shows Dermatology Educational Materials Often Lack Darker Skin Tones,” Stanford Human‑Centered AI (September 5, 2023).

    News‑Medical.net, “Current AI programs do worse at identifying skin lesions in people of color, research shows” (March 7, 2024).

    Stanford Medicine News Center, “AI improves accuracy of skin cancer diagnoses in Stanford Medicine-led study” (April 11, 2024).

    Center for Dermatology, “Why Annual Skin Cancer Screenings Are Essential for Early Detection”.

  • Can Weight‑Loss Drugs Save Heart Patients? A Friendly Look at the Latest Study

    Can Weight‑Loss Drugs Save Heart Patients? A Friendly Look at the Latest Study

    A Surprising Discovery: Slimming Drugs for Heart Health

    It’s the largest study of its kind and the results show GLP-1 agonists can cut in half heart patients risk of being hospitalized or dying early. What this means is that soon, certain weight loss drugs could be given to patients with heart conditions to help them live longer. Can weight‑loss drugs save heart patients? Does this sound too good to be true? Let’s dive in!

    A few years ago, drugs like Wegovy and Zepbound were headline news because of their near‑miraculous ability to help people shed pounds. They belong to a class of medications known as GLP‑1 agonists, which mimic a hormone that makes you feel full and slow the movement of food through your stomach. Originally designed to treat type 2 diabetes, they quickly became famous for weight loss.

    Now researchers say these same drugs might do something even more dramatic: cut in half the risk of heart failure patients being hospitalized or dying early. At the European Society of Cardiology conference in Madrid, a team from Mass General Brigham presented a huge study of more than 90,000 people with heart failure with preserved ejection fraction (HFpEF) who were obese and had type 2 diabetes. When they compared people starting the weight‑loss drugs semaglutide or tirzepatide with those starting another diabetes drug, sitagliptin, they found that semaglutide users had a 42 % lower risk of hospitalization or death and tirzepatide users had a 58 % lower risk.  The findings were published in JAMA and were described by experts as “dramatic.”

    What Are GLP‑1 Drugs and How Do They Work?

    GLP‑1 agonists are synthetic versions of a hormone called glucagon‑like peptide‑1, which helps regulate blood sugar and appetite. When you take one of these drugs, you tend to feel full sooner and stay full longer. Over time that leads to steady, meaningful weight loss, about 12 % of body weight on semaglutide and around 18 % on tirzepatide in clinical trials. These medications also improve blood sugar control, which is why they were first approved for diabetes.

    The idea that they could help heart patients isn’t totally new. In May 2025, another study showed that people taking semaglutide had a 20 % lower risk of heart attack, stroke or cardiovascular death, regardless of their starting weight. Scientists think the drugs’ benefits may extend beyond weight loss to anti‑inflammatory effects and improved blood vessel function.

    The Promise: Fewer Hospital Visits and Better Survival

    The new Mass General Brigham study is impressive because of its size and because it looked at “real world” patients outside of tightly controlled trials. All participants had heart failure with preserved ejection fraction (HFpEF), a common type of heart failure where the heart’s pumping function looks normal, but the muscle is stiff and can’t relax properly. HFpEF accounts for roughly half of all heart failure cases and is rising due to aging, high blood pressure, obesity and type 2 diabetes. Treatments are limited, so any therapy that improves outcomes is a big deal.

    By comparing patients who started semaglutide or tirzepatide with those who started sitagliptin, the researchers estimated how likely the GLP‑1 drugs were to prevent hospitalization or death. The results were striking: semaglutide users had a 42 % lower risk and tirzepatide users had a 58 % lower risk.  Interestingly, there was no meaningful difference between the two drugs.  Because this study used health‑care records rather than randomly assigning treatments, it can’t prove cause and effect. People who received GLP‑1 drugs may have been healthier in other ways. Randomised controlled trials will be needed to confirm the benefits and see how long they last.

    Understanding HFpEF: The Heart Problem That’s Hard to Treat

    To appreciate why this research matters, it helps to know what HFpEF is. In this form of heart failure, the left side of the heart pumps normally but can’t relax properly, causing blood to back up into the lungs and body. Symptoms include shortness of breath, swelling and fatigue. Because the pumping function looks fine on an echocardiogram, HFpEF is sometimes called “heart failure with a normal ejection fraction.” It currently has fewer proven treatments than the better‑known heart failure with reduced ejection fraction (HFrEF).

    HFpEF mostly affects older adults, especially those with high blood pressure, obesity or diabetes. With more than 60 million people worldwide living with heart failure, and about half of them having HFpEF, new therapies could make a huge difference.

    Things to Cheer and Worry About

    As exciting as these findings are, it’s important to look at the whole picture. GLP‑1 drugs come with side effects. A University of California San Francisco article notes that nausea, vomiting, fatigue, diarrhea and constipation are common. Doctors often start patients on low doses and increase gradually to help them adjust. For some people the drugs feel unbearable: one cardiologist described a patient who became severely dehydrated and developed an irregular heart rhythm after starting semaglutide.

    In rare cases, the drugs slow the stomach so much that contents remain for days, leading to stomach paralysis or bowel obstruction.  There are also concerns about their use in pregnancy and a lack of long‑term safety data. Meanwhile, a survey of people taking GLP‑1s found that about half experienced nausea, a third had diarrhea and one‑fifth reported vomiting; most said these were mild, but some reported them as serious.

    Cost and access are big barriers. Without insurance, a 28‑day supply of brand‑name GLP‑1 drugs like Ozempic, Wegovy or Mounjaro can cost about $1,000 a month.  Even with insurance, many plans only cover the drugs for diabetes, not obesity or heart failure, so patients often pay out of pocket.  Some companies now offer discount programs, Zepbound for $349 – $699 a month and Wegovy for $499, but that’s still a lot of money. When shortages hit in 2024 and 2025, compounding pharmacies stepped in with cheaper versions for about $199 a month, but those products aren’t FDA‑regulated and may vary in quality.

    Supply shortages and disparities persist. The U.S. Food and Drug Administration declared the national shortage over in February 2025, but some experts worry that as more people seek the drugs for weight loss or heart health, supply could tighten again. Surveys show that nonwhite patients are less likely to be prescribed GLP‑1s despite being at higher risk for diabetes and obesity. Many people who could benefit most live in rural areas or have low incomes and can’t afford or access the injections.

    What This Means for the Future

    Doctors are not going to start prescribing these drugs for heart failure right away. As one expert put it, “more evidence would be required before doctors could recommend rolling out weight‑loss drugs to heart patients specifically to cut their risk”. In other words, while the early results look promising, clinicians want to see data from randomized trials before they change practice. Ongoing studies will help determine whether GLP‑1 drugs truly reduce hospitalizations and deaths and which patients benefit most.

    In the meantime, these findings highlight the broader value of treating obesity and type 2 diabetes aggressively. Weight loss and good blood sugar control are already known to lower the risk of heart attack, stroke and death. GLP‑1 drugs may become part of the toolkit for managing heart failure, but they won’t replace the basics: a healthy diet, regular exercise, controlling blood pressure and taking medications like SGLT2 inhibitors or beta‑blockers when appropriate.

    Final Thoughts

    It’s tempting to see GLP‑1 injections as a magic bullet: they help people lose weight and might keep heart patients out of hospital. For some, they will be game‑changing. But every medicine has trade‑offs. These drugs can cause nausea or other side effects; they’re expensive and not always covered by insurance; and the most eye‑popping results so far come from an observational study that needs to be confirmed. If you have heart failure or are considering GLP‑1 therapy, talk to your doctor. Ask about the benefits and risks, and whether there are other treatments you should try first. As research continues, we’ll learn more about who stands to gain the most from these powerful medications and how to make them accessible to everyone who needs them.

    Sources

    • Press reports summarizing the Mass General Brigham study presented at the European Society of Cardiology conference: semaglutide reduced hospitalization or death by 42 %, and tirzepatide by 58 %.
    • Expert commentary on the study, noting both its promise and the need for more evidence.
    • The American Heart Association describes HFpEF as a type of heart failure where the heart pumps normally but cannot relax properly; it accounts for about half of all heart failure cases and is linked to aging, hypertension, obesity and diabetes.
    • A University of California San Francisco article lists common side effects of GLP‑1 drugs (nausea, vomiting, fatigue, diarrhea, constipation) and notes rare complications like stomach paralysis.
    • A RAND survey of U.S. adults taking GLP‑1 agonists reports that about half experienced nausea, a third had diarrhea and one‑fifth had vomiting; most said side effects were mild.
    • A WebMD report on cost and access explains that many people struggle to afford GLP‑1 drugs; without insurance they cost about $1,000 a month, and even with insurance coverage is often limited. Discount programs reduce the price but may still be out of reach; compounded versions were available during shortages but carry risks.
    • A press report on earlier research notes that semaglutide reduced the risk of heart attack, stroke or cardiovascular death by 20 %.